- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Fall 2016
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Fenoglide | Santarus | Fenofibrate Tablets | Mylan | indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia | 7/6/2016 |
Paxil CR | Apotex | Paroxetine Extended-Release Tablets | Lannett | used to treat depression | 7/11/2016 |
Temodar | Merck | Temozolomide Capsules | Mylan | indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment | 7/11/2016 |
Zegerid | Santarus | Omeprazole / Sodium Bicarbonate Capsules | Ajanta | short-term treatment of active benign gastric ulcer; active duodenal ulcer; erosive esophagitis (EE); symptomatic GERD; and the maintenance of healing of EE | 7/18/2016 |
Nilandron | Covis Pharmaceuticals | Nilutamide Tablets | ANI Pharmaceuticals | indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2) | 7/18/2016 |
Zegerid | Santarus | Omeprazole / Sodium Bicarbonate Capsules | Dr. Reddy's Laboratories | short-term treatment of active benign gastric ulcer; active duodenal ulcer; erosive esophagitis (EE); symptomatic GERD; and the maintenance of healing of EE | 7/18/2016 |
Zegerid OTC | Merck | Omeprazole / Sodium Bicarbonate OTC Capsules | Perrigo | short-term treatment of active benign gastric ulcer; active duodenal ulcer; erosive esophagitis (EE); symptomatic GERD; and the maintenance of healing of EE | 7/18/2016 |
Axert | Janssen | Almotriptan Malate Tablets | Ajanta | indicated for acute migraine pain treatment for adults and teens | 7/19/2016 |
Crestor | AstraZeneca | Rosuvastatin Calcium Tablets | Citron Pharma | is an antihyperlipidemic to prevent cardiovascular disease | 7/19/2016 |
Crestor | IPR Pharmaceuticals | Rosuvastatin Calcium Tablets | Aurobindo Pharma | is an antihyperlipidemic to prevent cardiovascular disease | 7/20/2016 |
Xeloda | Hoffmann-La Roche | Capecitabine Tablets | Hikma Pharmaceuticals / West-Ward Pharmaceuticals | indicated for adjuvant treatment in patients with Dukes' C colon cancer, as monotherapy in metastatic colorectal cancer, and in combination with docetaxel or as montherapy in patients with metastatic breast cancer | 7/20/2016 |
Ortho Tri-Cyclen | Johnson & Johnson | Norgestimate / Ethinyl Estradiol Tablets | Lupin | indicated for use by females of reproductive potential to prevent pregnancy | 7/20/2016 |
Crestor | AstraZeneca | Rosuvastatin Calcium Tablets | Mylan | is an antihyperlipidemic to prevent cardiovascular disease | 7/20/2016 |
Crestor | IPR Pharmaceuticals | Rosuvastatin Calcium Tablets | Apotex | is an antihyperlipidemic to prevent cardiovascular disease | 7/22/2016 |
Propecia | Merck | Finasteride Tablets | Mylan | treatment of male pattern hair loss (androgenetic alopecia) for men only | 8/1/2016 |
Dexedrine | Amedra Pharmaceuticals | Dextroamphetamine Sulfate Extended-Release Capsules | Mylan | indicated in narcolepsy and attention deficit disorder with hyperactivity as an integral part of a total treatment program with typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome | 8/1/2016 |
Gleevec | Novartis Oncology | Imatinib Mesylate Tablets | Teva | indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) | 8/5/2016 |
Fusilev | Spectrum Pharmaceuticals | Levoleucovorin for Injection | Hikma Pharmaceuticals / West-Ward Pharmaceuticals | indicated for rescue after high dose methotrexate therapy in osteosarcoma and for diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists | 8/16/2016 |
Nitrostat | Pfizer | Nitroglycerin Sublingual Tablets | Dr. Reddy's Laboratories | used to stop or prevent angina (chest pain). | 8/29/2016 |
Wellbutrin XL | Valeant | Bupropion Hydrochloride Extended-Release Tablets (XL) | Cipla | an antidepressant used to treat Major Depressive Disorder (MDD) and Seasonal Affective Disorder (SAD) | 8/30/2016 |
Enablex | Allergan | Darifenacin Extended-Release Tablets | Cipla | indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency | 9/2/2016 |
Wellbutrin SR | GlaxoSmithKline | Bupropion HCI Extended-Release Tablets | Dr. Reddy's Laboratories | an antidepressant used to treat Major Depressive Disorder (MDD) and Seasonal Affective Disorder (SAD) | 9/2/2016 |
Razadyne | Johnson & Johnson | Galantamine Tablets | Hikma Pharmaceuticals / West-Ward Pharmaceuticals | indicated for the treatment of mild to moderate dementia in patients with Alzheimer's disease | 9/2/2016 |
Ortho-Cyclen 28 | Ortho-McNeil | Femynor | Amneal | indicated for use by females of reproductive potential to prevent pregnancy | 9/8/2016 |
Cubicin | Merck Sharp & Dohme | Daptomycin for Injection | Teva | indicated for treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates | 9/15/2016 |
Zemplar | Abbvie | Paricalcitol Injection | Dr. Reddy's Laboratories | used for the prevention and treatment of high levels of parathyroid hormone in certain patients with chronic kidney disease | 9/19/2016 |
Cubicin | Merck | Daptomycin for Injection | Fresenius Kabi USA | indicated for treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates | 9/20/2016 |
Metadate CD | UCB | Methylphenidate Hydrochloride Extended-Release Capsules | Impax Laboratories | indicated for treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 9/22/2016 |
Zegerid | Santarus | Omeprazole / Sodium Bicarbonate Powder for Oral Suspension | Ajanta | short-term treatment of active benign gastric ulcer; active duodenal ulcer; erosive esophagitis (EE); symptomatic GERD; and the maintenance of healing of EE | 9/26/2016 |
Cymbalta | Eli Lilly | Duloxetine Capsules | Camber Pharmaceuticals | used to treat depression and anxiety | 9/27/2016 |
Epzicom | GlaxoSmithKline | Abacavir / Lamivudine Tablets | Teva | indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, abacavir and lamivudine tablets may help to: Reduce the amount of HIV-1 in affected patients' blood (viral load), and increase the number of CD4+ (T) cells in affected patients' blood to help fight off other infections | 9/29/2016 |
Fortamet | Watson | Metformin Hydrochloride Extended-Release Tablets | Mylan | indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | 9/30/2016 |
GENERICally Speaking Fall 2016
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.